InsidersTradesSigma
Follow the Catalyst Biosciences, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Catalyst Biosciences, INC. has published 28 insider filings. Market capitalisation: €526.1m. The latest transaction was filed on 27 October 2023 (J). Among the most active insiders: USMAN NASSIM. The full history is free.
28
Insider Decl.
n/a
Thresholds
€16,647
9 ops.
Buy Volume
n/a
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Catalyst Biosciences, INC. Strong Buy (bullish), based on 5 analysts. Average price target: US$31.00.
56Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 October 2023
Declarations28 total
5,371,304 sharesCommon StockSEC:0001140361-23-050019:0
24.541 sharesSeries Y Preferred StockSEC:0001140361-23-042367:0
24.573 sharesSeries Y Preferred StockSEC:0001140361-23-042365:0
6.5 sharesSeries Y Preferred StockSEC:0001140361-23-042369:0
28.228 sharesSeries Y Preferred StockSEC:0001140361-23-042368:0
895.217 sharesSeries Y Preferred StockSEC:0001140361-23-042366:0
3,250 shares@ US$0.4753.3% of flowCommon StockSEC:0001209191-22-045254:0
Canonical exit: 7 Nov 2022 (T+90)
3,250 shares@ US$0.4718.4% of flowCommon StockSEC:0001209191-22-045256:0
Canonical exit: 7 Nov 2022 (T+90)
3,250 shares@ US$0.4715.0% of flowCommon StockSEC:0001209191-22-045251:0
Canonical exit: 7 Nov 2022 (T+90)
3,250 shares@ US$0.460.0002% mcap100.0% of flowCommon StockSEC:0001209191-22-010403:0
Canonical exit: 10 May 2022 (T+90)
3,250 shares@ US$0.460.0002% mcap15.4% of flowCommon StockSEC:0001209191-22-010392:0
Canonical exit: 10 May 2022 (T+90)
3,250 shares@ US$0.460.0002% mcap19.7% of flowCommon StockSEC:0001209191-22-010407:0
Canonical exit: 10 May 2022 (T+90)
12,855 shares0Common StockSEC:0001209191-22-002485:0
12,308 shares0Common StockSEC:0001209191-22-002488:0
7,521 shares0Common StockSEC:0001209191-22-002482:0
1,824 shares0Common StockSEC:0001209191-21-059427:0
3,588 shares0Common StockSEC:0001209191-21-059424:0
2,980 shares0Common StockSEC:0001209191-21-059436:0
5,839 shares0Common StockSEC:0001209191-21-059429:0
2,858 shares0Common StockSEC:0001209191-21-059433:0
867 shares@ US$3.6248.8% of flowCommon StockSEC:0001209191-21-050759:0
Canonical exit: 7 Nov 2021 (T+90)
1,163 shares@ US$3.6256.1% of flowCommon StockSEC:0001209191-21-050757:0
Canonical exit: 7 Nov 2021 (T+90)
639 shares@ US$3.62100.0% of flowCommon StockSEC:0001209191-21-050758:0
Canonical exit: 7 Nov 2021 (T+90)
2,713 shares0Common StockSEC:0001209191-21-044691:0
5,542 shares0Common StockSEC:0001209191-21-044690:0
25 of 28 declarations
关于 Catalyst Biosciences, INC.
Catalyst Biosciences, Inc. (股票代码: CBIO) 是一家在美国纳斯达克市场上市的生物制药公司。该公司历史上总部位于加利福尼亚州南旧金山，成立于 2002 年。其商业模式长期以来一直是研究阶段的生物技术公司，而非商业制药公司：价值创造主要取决于科学进展、临床里程碑、知识产权、监管反馈和资本获取。([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm?utm_source=openai)) Catalyst 的核心身份围绕着工程化蛋白酶和基于蛋白酶的疗法构建，旨在解决严重的未满足医疗需求。美国证券交易委员会文件描述了一个专注于补体失调和相关炎症途径的管线，其项目旨在恢复补体稳态或选择性调节级联反应的特定组分。该公司强调了与补体相关的候选药物，例如改进的 CFI 蛋白酶项目和 C3/C4b 降解平台，以及早期在止血和罕见出血性疾病方面的工作。这种演变表明，该公司已多次调整其管线，以在利基疾病领域寻求差异化、高科学含量的机会。([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-10k_20211231.htm?utm_source=openai)) 从竞争角度来看，Catalyst 在医疗保健领域最具挑战性的细分市场之一：早期生物技术领域运营。其竞争地位并非由收入规模或商业足迹决定，而是由平台新颖性、管线选择性和产生临床概念验证的潜力决定。与规模更大、资金更充足的同行相比，Catalyst 是一家规模小得多的公司，因此更容易受到临床挫折、融资需求和战略调整的影响。对于投资者而言，这使得 CBIO 成为一只高度事件驱动的股票，其上涨由数据公布驱动，下跌则与开发风险和稀释风险相关。([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-10k_20211231.htm?utm_source=openai)) 历史上，该公司的运营集中在美国主要的生物技术集群南旧金山，这有助于人才招聘和靠近更广泛的生命科学生态系统。公开披露还显示，该公司已使用美国证券交易委员会文件和公司更新来传达战略变化，包括融资事件和持续的投资组合调整。最近，公开可用的文件和内部人交易披露表明，围绕治理和所有权变更的持续公司活动，这进一步强化了投资者应密切关注美国证券交易委员会 Form 4s、8-Ks 和管线更新的观点。简而言之，Catalyst Biosciences 仍然是一家以科学为主导、运营基础狭窄、估值可能对新闻流高度敏感的小盘纳斯达克生物技术公司。([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm?utm_source=openai))
